A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

Completed · Phase 3

Conditions studied: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors

In brief

The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or IX in 12 patients ( birth to \<6 years old), and 12 patients (≥6 years old to \<12 years old).

Key facts

Study ID

NCT02448680

Run by

Laboratoire français de Fractionnement et de Biotechnologies

People needed

25

Starts

2015-12-07

Expected to finish

2017-08-30

Last updated by the study team

2022-02-25

Who can join

Age: any, up to 11. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• be male with a diagnosis of congenital hemophilia A or B of any severity
• have one of the following:
• a positive inhibitor test BU ≥5, OR
• a Bethesda Unit (BU) <5 but expected to have a high anamnestic response to FVIII or FIX, as demonstrated from the patient's medical history, precluding the use of factor VIII or IX products to treat bleeding episodes, OR
• a BU <5 but expected to be refractory to increased dosing of FVIII or FIX, as demonstrated from the patient's medical history, precluding the use of factor VIII or IX products to treat bleeding episodes
• be aged from birth to <12 years old
• have experienced at least 3 bleeding episodes of any severity in the past 6 months
• parents or legal guardians must be capable of understanding and be willing to comply with the conditions of the protocol
• parents or legal guardians must have read, understood, and provided written informed consent

You may not qualify if…

• have any coagulation disorder other than hemophilia A or B
• be immunosuppressed (i.e., the patient may not be receiving systemic immunosuppressive medication; cluster of differentiation 4 (CD4) counts at screening must be >200/µL)
• have a known allergy or hypersensitivity to rabbits
• have platelet count <100,000/mL
• have had a major surgical procedure (e.g. orthopedic, abdominal) within 1 month prior to first administration of study drug
• have received an investigational drug within 30 days of first study drug administration, or be expected to receive such drug during participation in this study

Where it is running

• University of Colorado Denver Hemophilia & Thrombosis Center — Aurora, Colorado, United States
• Jimmy Everest Center for Cancer and Bleeding Disorders — Oklahoma City, Oklahoma, United States
• UT Southwestern Medical Center at Dallas / Children's Medical Center — Dallas, Texas, United States
• University Multiprofile Hospital for Active Treatment "Sveti Georgi" — Plovdiv, Bulgaria
• University Hospital Motol — Prague, Czechia
• Hematology of Department Hemophilia and Thromboses center — Tbilisi, Georgia
• Worthwhile Clinical Trials — Benoni, South Africa
• National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology (Ukraine) — Kyiv, Ukraine
• Institute of Blood Pathology and Transfusion Medicine — Lviv, Ukraine

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.